Brain and behavioral effects linked to autism may be temporarily reversible in adults using a single dose of the immunosuppressive drug rapamycin, according to a study published in Nature Communications by scientists at UCLA Health.
UCLA Health Study Traces Autism-Like Symptoms to Prenatal Inflammation
To investigate potential treatment pathways, scientists exposed pregnant mice to a stimulus that caused mild inflammation. According to the study, this maternal inflammation triggered autism-like changes in the offspring, leading to persistent inflammation in both the brain and the body.
Researchers noted that this systemic inflammation correlates with behaviors commonly associated with autism, such as abnormal brain growth, seizures, and heightened sensitivity to sensory input.
Single Dose of Rapamycin Rapidly Improves Brain Signaling
To test potential reversals, the research team administered a single dose of rapamycin to adult mice exhibiting autism-like symptoms. Within two hours, the drug significantly improved brain signaling and behavioral markers, according to the study.
Rapamycin calmed unusually active neurons, eased repetitive behaviors, and reduced sensory overresponsivity. Furthermore, brain regions that previously failed to communicate properly began showing more typical patterns of interaction.
Did you know? mTOR stands for “Mechanistic Target of Rapamycin.” It acts as the cell’s master switch for regulating cell division, growth, metabolism, and survival. Rapamycin is a prescription immunosuppressant and mTOR inhibitor.
How Rapamycin Alters Gene Activity Without Structural Remodeling
To understand the rapid response, scientists examined gene activity in brain cells before and after administering the drug. The data revealed that rapamycin altered brain function and electrical activity directly, rather than rebuilding the underlying physical structure of the brain, a process that typically requires extended periods.
According to the findings, this mechanism reversed abnormal patterns of gene expression tied directly to autism and epilepsy.
Future Treatment Implications and Current Limitations
While the results point toward novel targets for managing difficult symptoms like sensory overresponsivity, researchers emphasize that rapamycin is not an immediate autism treatment. The benefits observed in the mouse study were temporary, and the drug’s effects occurred too rapidly to address the physical brain changes caused by initial inflammation.
Additionally, rapamycin is toxic with repeated use, and the mice developed a tolerance after several weeks, diminishing the potency of initial doses. Dr. Neil Harris, the study’s co-senior author, told Science Daily that the results serve as a foundational starting point.
“This points toward new therapeutic targets like sensory circuit neuromodulation or balancing neuronal inhibition and excitation, rather than toward rapamycin itself as a treatment,” Dr. Harris said.
Dr. Harley Kornblum, the study’s senior author, added in an interview with Science Daily that the rapid functional normalization highlights new mechanisms for potential interventions. “It suggests the adult brain may be more adaptable than we assumed, even when the underlying structural changes from early development are still there,” Dr. Kornblum stated.
Frequently Asked Questions
Is rapamycin approved to treat autism in humans?
No. Rapamycin is a prescription immunosuppressant primarily used to prevent organ transplant rejection. Human clinical trials for autism treatments based on these findings are not currently scheduled.
Why are the study’s results considered temporary?
According to researchers, the positive behavioral and neurological effects observed in mice faded after a short period, and subjects developed a drug tolerance within several weeks of repeated exposure.
What causes the autism-like symptoms in the UCLA Health model?
The study found that mild inflammation induced during pregnancy causes persistent inflammation in the offspring’s brain and body, triggering abnormal brain growth, seizures, and sensory sensitivities.
What are your thoughts on these findings regarding brain adaptability? Share your perspective in the comments below, and subscribe to our newsletter for ongoing updates on neurological research.